Viatris Inc. (VTRS)
Salud / Farmacéutica genérica y de marca
Viatris combines complex generics and off-patent brands with global manufacturing scale; it is going through a strategic review that cut leverage to 2.9 times and raised 2026 guidance twice, but growth remains structurally low from loss of exclusivity and pricing pressure, and it trades at a generic-pharma multiple that already reflects much of that risk.
- Price
- $16.61
- Intrinsic value (5y, base)
- $29
- Total annual return (5y)
- 14.0%
- Status (nominal)
- Undervalued
- Margin of safety
- +34%
The essentials
- Revenue stabilized in the first half of 2026, with full-year guidance raised twice in a row.
- Gross leverage fell to 2.9 times after the sale of the Biocon stake and a balanced capital allocation across debt paydown, dividend, and buybacks.
- The GAAP result carries goodwill impairments and non-recurring restructuring charges; adjusted earnings is the metric that supports the valuation.
Intrinsic value — two valuation methods
Total return at 5 years: 14.0%/year = 11.6% appreciation + 2.4% dividend. The target price ($29) is ex-dividend; the $2 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $62 · Multiples $25) exceeds the market price ($17).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $17 trades ~34.1% below its value discounted to today (~$25); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — Infravalorado: the target price ($29) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$16.
Thesis
The business
Viatris is a globally scaled pharmaceutical company with a narrow and eroding moat: the manufacturing and intellectual property advantage does not offset the structural pricing pressure in generics or the loss of exclusivity in branded products. 2026 guidance was raised twice in a row and leverage fell to 2.9 times, signs of stabilization, but return on capital remains structurally compressed by the weight of goodwill inherited from the 2020 merger.
The valuation
Undervalued - the business is valued at the generic-pharma exit multiple over adjusted net income, the metric that expenses the goodwill impairment and restructuring charges that distort the GAAP result. Under the base-case path, the 5-year value implies a +14% annual return at the market price, against the current price of $17.
The margin of safety
It trades at a real discount to value, though short of the required margin of safety. The expected return comes from comparing the market price against the value projected 5 years out, discounted at the method's floored risk-free rate; the business-specific risk -restructuring execution, regulatory pressure in Indore, loss of exclusivity- is charged in the adverse scenario and in the required margin, not in the base-case multiple.
What to watch
The central disconfirmer is whether the restructuring (EWSR) delivers the promised US$600-700 million in annual savings without sacrificing additional volume: if adjusted earnings per share fails to resume a sustained growth trajectory beyond the rebound guided for 2026, the stabilization thesis collapses and the business reverts to reading as structural decline with a multiple that should compress toward the floor of the band.
Educational / informational. Does not constitute investment advice.